Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Anticholinergic vs. Botox Comparison Study (ABC)
This study has been completed.
Study NCT01166438 Information provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First Received on July 19, 2010. Last Updated on January 7, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Urge Urinary Incontinence
Overactive Bladder
Additional conditions recognized in this trial
Urinary Bladder, Overactive
Urinary Incontinence
Urinary Incontinence, Urge
More general conditions related to this trial
Signs and Symptoms
Urinary Bladder Diseases
Urination Disorders
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
Botulinum toxin A (Botox A®)
Solifenacin 5mg
Solifenacin 10mg
Trospium chloride
Additional drug interventions recognized in this trial
Botulinum Toxins
Botulinum Toxins, Type A
Cholinergic Antagonists
Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate
More general drug interventions related to this trial
Analgesics
Anti-Dyskinesia Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neuromuscular Agents
Neurotransmitter Agents
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Susan Meikle, MD MSPH
Office of Research on Women's Health (ORWH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Back to top of Main Content
